Some investors asked questions on the investor interaction platform: Shanghai Junshi Biosciences Co.Ltd(688180) vv116 is a derivative of redcivir from the perspective of molecular structure, and the anti covid-19 virus effect of stephanine is 7.7 times that of redcivir. As an upstream reagent supplier of life sciences and a rare listed company of stephanine in China, your company can give play to its first mover advantage and cooperate with relevant parties to integrate the stephanine industrial chain (upstream planting, midstream extraction, downstream animal test, and even later clinical test and market promotion), so as to contribute to the global anti epidemic. Suggestions: 1. The company optimizes the plant extraction process or chemical synthesis route of stephanine; 2. The company participated in the scientific research of stephanine against covid-19 virus: animal test and clinical test.
Yuningwei (301166. SZ) said on the investor interaction platform on May 18 that the stephanine sold by our company is used in the research stage as a biochemical reagent. This product is an ODM product of abixin, a subsidiary of the company, which is not self-produced. In the future, based on the brand image of antibody experts, the company will introduce more products and equipment through self-development and the introduction of third-party brands around antibodies and antibody related reagents, so as to continuously enhance the one-stop service ability of the company’s life science.
